State coverage
Medicaid, for obesity: Does not cover. Coverage for overweight and obesity ended January 1, 2026. Saxenda is no longer covered for anything.
Pennsylvania ended coverage of GLP-1 drugs for overweight and obesity on January 1, 2026, by bulletin. If you need the citable document — the thing a reporter or a benefits counselor actually has to produce — it is Medical Assistance Bulletin dated November 24, 2025, signed by the Deputy Secretary of the Office of Medical Assistance Programs, and the state republished the change as a formal notice in the Pennsylvania Bulletin a month later.
Two details in that bulletin get lost in summaries of it. Saxenda was not merely dropped for obesity; the state says it is no longer covered for any indication at all. And obesity drugs that are not GLP-1s stayed covered, with the preferred ones available without prior authorization — so "Pennsylvania dropped weight-loss coverage" is not quite what the document says.
The bulletin also answers the managed care question directly, which is unusual and useful: the medical-necessity guidelines are used in the fee-for-service and managed care delivery systems alike. Your HealthChoices plan does not get to reach a different answer, though the bulletin notes the procedure for requesting authorization may differ, so ask your own plan how to file.
The state's own words, effective January 1, 2026: "drugs containing a GLP-1 receptor agonist will not be covered for the treatment of overweight or obesity. Drugs containing a GLP-1 receptor agonist will continue to be covered for all other medically accepted indications with a prior authorization. Saxenda (liraglutide) will no longer be covered for any indication."
Pennsylvania Department of Human Services, Office of Medical Assistance Programs, effective January 2026 · source · read August 2026
Obesity drugs that do not contain a GLP-1 stayed on. The bulletin says they "will continue to be covered by the MA Program," and that the ones marked preferred on the statewide list are available without prior authorization, naming phentermine capsules and tablets, so long as quantity limits are not exceeded.
Pennsylvania Department of Human Services, Office of Medical Assistance Programs, effective January 2026 · source · read August 2026
Being in a managed care plan does not change the answer. The bulletin states that the guidelines used to decide medical necessity for these drugs "will be utilized in the fee-for-service and managed care delivery systems," and tells enrollees in managed care to take questions about how to request prior authorization to their own plan.
Pennsylvania Department of Human Services, Office of Medical Assistance Programs, effective January 2026 · source · read August 2026
The change also ran as a formal state notice, which is the version to cite if you need one in the public record: "Medical Assistance Program Compensable Service Change: GLP-1 Drugs to Treat Overweight and Obesity," 55 Pa.B. 8828, published Saturday, December 27, 2025, announcing discontinuation "effective for dates of service on and after January 1, 2026."
Pennsylvania Bulletin, Department of Human Services, effective December 2025 · source · read August 2026
Pennsylvania's appeal window is shorter than the federal ceiling, and this is the one number on this page worth writing down. The state regulation gives you "Thirty days from the date of written notice of a decision or action," and 60 days where no written notice was required or sent. Appeals filed late "will be dismissed without a hearing." A separate 6-month window applies where the agency failed to send a required notice or made an administrative error.
55 Pa. Code §275.3, Pennsylvania Code, effective December 1980 · source · read August 2026
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.